✉ Email this page to a colleague
« Back to Dashboard
GSI-136 is an investigational drug.
There have been 13 clinical trials for GSI-136. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2002.
The most common disease conditions in clinical trials are Alzheimer Disease, Osteosarcoma, and Neoplasms. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, National Cancer Institute (NCI), and Baylor College of Medicine.
Recent Clinical Trials for GSI-136
|Nirogacestat in Ovarian Granulosa Cell Tumors||SpringWorks Therapeutics, Inc.||Phase 2|
|EEG Changes in Pediatrics With Language Dysfunction Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. EEG Changes in Pediatrics With Language Dysfunction||Ain Shams University||Phase 3|
|Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen||Azienda Ospedaliera San Paolo||Phase 3|